Experienced in Hereditary Fructose Intolerance

Dr. Shawn E. Mccandless

Medical Genetics | Pediatrics
University Physicians Incorporated
13123 E 16th Ave, Children's Hospital Colorado, 
Aurora, CO 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Experienced in Hereditary Fructose Intolerance
University Physicians Incorporated
13123 E 16th Ave, Children's Hospital Colorado, 
Aurora, CO 
OverviewInsuranceLocationsClinical Research

Overview

Shawn Mccandless is a Medical Genetics specialist and a Pediatrics provider in Aurora, Colorado. Dr. Mccandless and is rated as an Experienced provider by MediFind in the treatment of Hereditary Fructose Intolerance. His top areas of expertise are Urea Cycle Disorders (UCD), Prader-Willi Syndrome, Pyruvate Decarboxylase Deficiency, and Pyruvate Dehydrogenase Deficiency. Dr. Mccandless is currently accepting new patients.

His clinical research consists of co-authoring 58 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Hereditary Fructose Intolerance.

Graduate Institution
Temple University School Of Medicine
Specialties
Medical Genetics
Pediatrics
Licenses
Clinical Genetics in OH
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Medica

Locations

UNIVERSITY PHYSICIANS INCORPORATED
13123 E 16th Ave, Children's Hospital Colorado, Aurora, CO 80045

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Natural History and Advanced Genetic Study of Pyruvate Dehydrogenase Complex Deficiencies (North American Mitochondrial Disease Consortium, Rare Diseases Clinical Research Network, Project 7413)
Natural History and Advanced Genetic Study of Pyruvate Dehydrogenase Complex Deficiencies (North American Mitochondrial Disease Consortium, Rare Diseases Clinical Research Network, Project 7413)
Enrollment Status: Recruiting
Publish Date: September 19, 2024
Intervention Type: Other
Longitudinal Study of Urea Cycle Disorders
Longitudinal Study of Urea Cycle Disorders
Enrollment Status: Recruiting
Publish Date: February 13, 2024
An Open Label Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate (GPB; RAVICTI®) in Pediatric Subjects Under Two Years of Age With Urea Cycle Disorders (UCDs)
An Open Label Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate (GPB; RAVICTI®) in Pediatric Subjects Under Two Years of Age With Urea Cycle Disorders (UCDs)
Enrollment Status: Completed
Publish Date: July 01, 2024
Intervention Type: Drug
Study Phase: Phase 4
An Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Extended-Release Tablets in Participants With Prader-Willi Syndrome With a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period
An Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Extended-Release Tablets in Participants With Prader-Willi Syndrome With a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period
Enrollment Status: Completed
Publish Date: April 19, 2024
Intervention Type: Drug
Study Drug: DCCR (diazoxide choline controlled release tablets)
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome
A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension
Enrollment Status: Active_not_recruiting
Publish Date: September 14, 2023
Intervention Type: Drug
Study Drug: Pitolisant
Study Phase: Phase 2
Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS)
Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS)
Enrollment Status: Completed
Publish Date: July 26, 2022
Intervention Type: Drug
Study Drug: Intranasal carbetocin
Study Phase: Phase 3
Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia
Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics of GLWL-01 in the Treatment of Patients With Prader-Willi Syndrome
A Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics of GLWL-01 in the Treatment of Patients With Prader-Willi Syndrome
Enrollment Status: Completed
Publish Date: March 27, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

58 Total Publications

ACAD9 treatment with bezafibrate and nicotinamide riboside temporarily stabilizes cardiomyopathy and lactic acidosis.
ACAD9 treatment with bezafibrate and nicotinamide riboside temporarily stabilizes cardiomyopathy and lactic acidosis.
Journal: Mitochondrion
Published: January 03, 2024

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile